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ABSTRACT
Introduction Relieving gastrointestinal (GI) symptoms 
was identified as a ‘top ten’ priority by our James Lind 
Alliance Priority Setting Partnership in cystic fibrosis (CF). 
We conducted an online survey to find out more about the 
effect of GI symptoms in CF.
Methods We co- produced an online survey distributed to 
the CF community via web- based platforms. The survey 
consisted of open and closed questions designed to help 
us learn more about the effects of GI symptoms for people 
with CF (pwCF). We analysed the data using descriptive 
statistics and thematic analysis. We promoted the survey 
via social media and web- based platforms which allowed 
respondents from any country to take part. Our participants 
came from the CF community, including: adults and 
children with CF, parents and close family of pwCF and 
healthcare professionals (HCPs) working with pwCF.
Results There were 276 respondents: 90 (33%) pwCF, 
79 (29%) family, 107 (39%) HCPs. The most commonly 
reported symptoms by lay respondents were stomach 
cramps/pain, bloating and a ‘combination of symptoms’. 
The top three symptoms that HCPs said were reported to 
them were reduced appetite, bloating and constipation. 
Almost all (94% (85/90)) HCPs thought medications helped 
to relieve GI symptoms but only 58% (82/141) of lay 
respondents agreed.
Conclusions Our survey has shown that GI symptoms 
among our participants are prevalent and intrude on daily 
lives of pwCF. There is a need for well- designed clinical 
studies to provide better evidence for management of GI 
symptoms and complications.
INTRODUCTION
Cystic fibrosis (CF) is the most common auto-
somal recessive inherited disease in people of 
European descent.1 It was once considered 
a disease of childhood as survival was rarely 
beyond the childhood years. With the advent 
of new treatments and novel drugs, people 
with CF (pwCF) are now living longer and 
often well into adulthood. For a baby born in 
2018, the median life expectancy is now 47.3 
years.2 The respiratory system is usually the 
main focus of treatment as respiratory disease 
remains the major cause of morbidity and 
mortality in CF.2 However, CF is a multisystem 
disease which necessitates a burdensome 
regimen of treatments. The CF landscape is 
changing and problems which may have been 
overlooked are now becoming a priority for 
people living with the condition and those 
providing CF care.
The gastrointestinal (GI) system is 
commonly affected in pwCF, the majority of 
whom have pancreatic insufficiency, requiring 
pancreatic enzyme supplements with meals.3 
In any 1 year, around 5% of patients will suffer 
the most severe GI complication, distal intes-
tinal obstruction syndrome (DIOS).2 The 
prevalence of liver disease is around 13%.2 GI 
symptoms which are reported in CF include: 
bloating, flatulence, abdominal pain and 
gurgling (borborygmi), with a prevalence of 
around 65%.4 With improved life expectancy, 
symptoms which previously received little 
attention are now having a greater impact 
on the lives of those with GI symptoms. The 
burden of GI symptoms in pwCF is higher 
than the general population. For example, 
Key messages
 ► How to relieve gastrointestinal (GI) symptoms in cys-
tic fibrosis (CF) was identified as a top research pri-
ority, but required further work to better understand 
the research question.
 ► We were able to identify the common symptom(s) 
and their impact on daily life in CF, including differ-
ences between lay and professional expectations of 
symptom relief.
 ► We hope that our findings will help inform well- 
designed clinical studies to provide better evidence 
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irritable bowel syndrome (characterised by abdominal 
pain, bloating, flatulence, diarrhoea and/or constipa-
tion) affects 10%–25% of the UK population, only half of 
whom will present to primary care.5
We recently carried out a James Lind Alliance Priority 
Setting Partnership in CF which resulted in a ‘top ten’ 
list of research priorities decided jointly by health-
care professionals (HCPs) and the patient community 
through online surveys and a final workshop.6 Some of 
these priorities were broad topics which did not trans-
late readily into testable hypotheses. The priority ranked 
in position two was: ‘How can we relieve gastro- intestinal 
symptoms such as stomach pain, bloating and nausea?’. 
In a continuation of the priority setting work and in 
conjunction with the CF community, we aimed to:
1. Understand the prevalence and impact of GI symp-
toms in CF.
2. Gather ideas for future clinical research into ap-
proaches to relieving GI symptoms.
Some results of this work have been previously 
published as an abstract7 and shared on social media with 
the CF community.
METHODS
The UK National Institute for Health Research (NIHR) 
supports the James Lind Alliance and agreed to us contin-
uing our priority setting work under the branding ‘James 
Lind CF2’ to investigate some of the research questions 
from the original priority setting partnership in more 
depth. The protocol for this continuation work can be 
found here (also online supplemental file 1) in https:// 
nottingham- repository. worktribe. com/ output/ 1195186. 
The Standards for Reporting Qualitative Research 
Reporting guidelines were used to report the methods 
used.8
Survey development
A steering group, representative of the CF community 
(both patients/parents and HCPs), guided the produc-
tion of an electronic questionnaire (SurveyMonkey). The 
survey (online supplemental file 2) was designed to help 
us understand how GI symptoms impact on the daily lives 
of pwCF and the measures they are already taking to help 
alleviate or avoid them. The survey included a mixture 
of closed and open questions and there was opportunity 
to expand in free text comment boxes. After an initial 
screening question to determine eligibility, the survey was 
divided into separate streams for HCPs and lay respond-
ents although we aimed to elicit the same information 
from different perspectives. Questions related to three 
main themes:
1. Presence of a diagnosed GI complication (lay respon-
dents only).
2. Symptoms (including type, frequency and severity).
3. Relief of symptoms (including medications, dietary/
exercise factors, non- medical interventions).
Data collection
The survey was promoted online via Twitter (@ques-
tionCF), professional networks, UK CF Trust, US CF 
Foundation and NIHR. It was an open invitation to 
anyone in the CF community rather than it being sent to 
a discreet sample of the population.
The survey was anonymous and where contact details 
were left for further interest in the study, these were sepa-
rated from the survey data and stored in compliance with 
General Data Protection Regulation guidelines. Partici-
pants were asked to read and agree to our privacy state-
ment before progressing through to the survey. It was 
designed to be as inclusive as possible, with no restric-
tions on age or location, and was open for a period of 
4 weeks between June and July 2018. The University of 
Nottingham Research Ethics Committee deemed this 
programme of work not to require ethical approval.
Data analysis
The data were downloaded from SurveyMonkey to 
Microsoft Excel for analysis of closed questions including 
a description of the respondent demographics and 
frequency of responses.
Free text data were downloaded to NVivo V.12 for 
thematic analysis. This was done using an iterative 
process using content and thematic analysis. The word 
frequency function was used for questions where there 
was free text content to help generate themes. Linked 
words such as ‘bloat’ and ‘bloating’ were combined and 
commonly used words that did not relate directly to the 
results were removed (eg, ‘sometimes’, ‘symptoms’). 
These themes were then applied across the whole dataset 
and the data were coded into these themes. Many of the 
comments fell into more than one theme and so were 
recorded separately under each theme to which the 
comment related. It is possible that this could lead to an 
over representation of some responses but it makes the 
distinction between the quantitative numbers of people 
reporting that they experience a particular symptom 
and the frequency with which it is mentioned across the 
whole dataset. The coding was validated by two authors to 
ensure consistency across the emergent themes and how 
the data were assigned to each theme (SS, NR).
Patient and public involvement
This work was driven by patient and public involvement, 
and this remained central to all stages of design, imple-
mentation and dissemination. The study was guided by 
a steering group which included two pwCF and a parent 
of children with CF. They were all involved in the design 
of the study, communication and interpretation of the 
results. Our lay representatives were instrumental in 
designing the survey to ensure it would be clear and 
understandable and also helped publicise the survey to 
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RESULTS
In total, 276 survey responses were received including 90 
(33%) from pwCF; 79 (29%) from parents, relatives or 
friends and 107 (39%) responses from HCPs. Almost half 
of the HCPs (44%, n=47) were dietitians. Median age of 
respondents was 37 years (range 15–74 years); median 
age of pwCF (including children with a parent answering 
on their behalf) was 12 years (range 0–74 years). We had 
responses from 15 countries, with 171 (62%) from the 
UK and 20 (7%) from the USA. Not all survey partici-
pants responded to each question so, where we present 
numbers and percentages, we have stated the denomi-
nator. Number of respondents to each question is given 
in online supplemental file 3.
Diagnosed pancreatic insufficiency and GI complica-
tions of CF were reported by a large number of our lay 
respondents, with 84% (132/157) having been diagnosed 
with pancreatic insufficiency; 39% (61/157) having had 
DIOS; 20% (32/157) having CF- related liver disease 
(CFRLD) and 32% (50/157) having had meconium ileus 
in the newborn period. Of the respondents who reported 
these conditions, almost half had at least two diagnoses 
(48%, 76/157) and a small percentage reported all four 
diagnoses listed (6%, 10/157).
All of the participants who reported pancreatic insuffi-
ciency also reported having experienced GI symptoms at 
some time compared with 26 out of 36 (72%) pancreatic 
sufficient participants.
Figure 1 shows the most common symptoms affecting 
quality of life in pwCF (figure 1A) and the frequency with 
which symptoms occur (figure 1B). The most commonly 
reported symptoms were stomach cramps/pain, bloating 
and a ‘combination of symptoms’ (this was reported as 
the concomitant effect of symptoms occurring together 
including gas, pain, nausea, bloating, diarrhoea and 
vomiting). The top three symptoms that HCPs said were 
reported to them were reduced appetite, bloating and 
constipation (figure 1C). Missing school or work because 
of GI symptoms was reported by 66% (97/146) of the 
lay respondents and a similar proportion said that symp-
toms have affected their confidence or self- image (65%, 
95/145). While 95% (147/155) reported being able 
to discuss GI symptoms with their CF team, only 26% 
(41/155) reported having the opportunity to discuss 
these with a gastroenterologist on their CF team.
We asked HCPs and pwCF whether they felt that 
medications helped to relieve GI symptoms and while 
94% (85/90) of HCPs thought that they did, only 58% 
(82/141) of lay respondents felt the same. Figure 2 
shows which types of medications were reported to help 
the most, with the top two for HCPs being laxatives and 
antacid medication and the top two for lay respondents 
being antacid medication and pancreatic enzymes. Only 
half of lay respondents felt that laxatives helped to relieve 
symptoms. We also asked if any non- medical interven-
tions, such as diet and exercise, helped relieve symptoms. 
Just under half of our lay respondents reported that 
symptoms were relieved by non- medical interventions 
(46%, 58/126). Of those respondents who answered 
this question, 28% (35/126) felt that diet helped and 
18% (23/126) thought that exercise improved symp-
toms. A higher proportion of HCPs felt that a change 
of diet helped to relieve symptoms (52%, 46/88). Other 
methods used by pwCF to relieve GI symptoms included 
massage, heat, probiotics, keeping hydrated and avoiding 
triggers such as over- eating.
Thematic analysis
We identified recurrent themes during the analysis of the 
free text data. The themes mentioned most frequently 
(figure 3) focused on physical effects such as pain, discom-
fort and bloating, and how this impacts on everyday life.
I cannot go to work when I have stomach pain and 
cramps as the pain makes it impossible to concentrate, 
Figure 1 GI symptoms experienced by pwCF. (A) 
Symptoms which most affect quality of life for pwCF. (B) 
Symptoms which are experienced every day or most days. 
(C) Top three symptoms affecting quality of life for pwCF 
and the top three complained about to HCPs. HCPs, 
healthcare professionals; pwCF, people with cystic fibrosis.
Figure 2 Relief of symptoms. HCP and lay views on 
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in general I get the stomach pain and cramps when 
I have diarrhoea so I wouldn’t want to go to work as 
it’s a shared toilet and would feel self- conscious that I 
was up and down from my desk to go to the toilet. It’s 
embarassing. (pwCF, UK)
If I’m cramping then I can’t work or exercise. (pwCF, 
Canada)
Constant stomach pain, enormous bloating, 
unpredictable bowel movements—it has been 
debilitating for my daughter, who can’t often exercise 
properly, which is bad for her chest and general 
health and wellbeing. She often misses social events. 
(Parent of a child with CF, England)
Bloating to the extent that pwCF felt as though they 
‘looked pregnant’ and being unable to wear clothes of 
their choice was mentioned frequently along with the 
concomitant effect on self- image and self- esteem.
I now have to buy clothes with my bloated stomach in 
mind. I feel self- conscious when I am bloated. I try to 
hide my bloating from others. (pwCF, UK)
Feeling bloated a lot of the time and therefore 
feeling uncomfortable with the way you feel and 
look. Having to choose your clothing so it doesn’t 
show your bloated stomach. (pwCF, UK)
Embarrassing when you have gas and self- conscious 
about my body when I have a distended stomach. 
(pwCF, Canada)
We also asked our respondents what measures they 
found helped control GI symptoms. Responses included 
medications that helped, along with non- pharmaceutical 
interventions such as diet, exercise and alternative thera-
pies. A wide range of measures were reported, shown in a 
frequency word cloud (figure 4).
Daily probiotics, eating more vegetables and lower 
refined carbohydrates has made my bloating and gas 
virtually normal. (pwCF, Australia)
I hold a hot water bottle on my stomach area and it 
relieves the pain and also seems to help get things 
moving. (pwCF, UK)
DISCUSSION
Our survey has shown that within our respondent group 
GI symptoms are prevalent, intrusive and have a daily 
impact on the lives of pwCF and those living and working 
with them. Common symptoms reported are pain, 
bloating and wind. There is a difference between lay 
respondents and HCPs with regard to whether they feel 
symptoms are eased by medication, with a higher propor-
tion of HCPs feeling that medications relieved symptoms 
than lay respondents. Themes emerging from the quali-
tative analysis were largely around feelings of embarrass-
ment, poor self- image and effect on everyday life.
Using an anonymous survey has allowed us to learn 
more about the impact of GI symptoms on pwCF than 
would be possible through interviews or focus groups. The 
use of a web- based platform, while necessary to prevent 
cross- infection from face to face contact, has meant that 
our survey was accessible to participants internationally 
and we encouraged honesty and openness. Many of the 
free text comments related to embarrassment and it is 
possible that this is a subject which pwCF do not find easy 
to discuss with their CF team.
Traditionally CF treatment has had a respiratory focus 
as respiratory failure is the most common cause of death 
in pwCF.9 However, most pwCF have pancreatic insuf-
ficiency necessitating pancreatic enzyme replacement 
therapy3 and all pwCF, completing a CF- specific question-
naire, reported GI symptoms in the preceding 3 months.10 
Tools for assessing GI symptoms in pwCF are still in devel-
opment and scoring systems designed for other GI condi-
tions are often used in CF (eg, GI Symptom Rating Scale; 
Figure 3 Themes emerging from the free text responses 
and direct quotes relating to the impact of GI symptoms. 
GI, gastrointestinal.
Figure 4 Word cloud showing other interventions which 
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Irritable Bowel Syndrome Symptom Severity Score).4 
Treatment guidelines focus on optimising nutrition, 
pancreatic enzyme supplements and the management of 
DIOS, but acknowledge the lack of high- quality evidence 
to guide recommendations.11 Current UK National Insti-
tute for Health and Care Excellence guidelines outline 
treatment regimens to maintain optimum nutritional 
status but there is little guidance on symptom control.12 
There is imprecision in the terminology used for GI 
symptoms which may lead to a difference between HCPs 
and lay people reporting symptoms.
The study highlights the need for evidence- based treat-
ments to alleviate distressing GI symptoms in addition to 
optimisation of current available treatments. It is clear 
that pwCF already use a range of different methods in an 
attempt to control symptoms including medications and 
non- medical interventions. A recent Cochrane review 
included 12 randomised controlled trials that looked 
at probiotics for CF but none of the trials reported on 
GI symptoms.13 Early work using MRI is aiming to iden-
tify physiological markers of where the CF GI system 
differs from that of healthy controls.14 New treatments 
that correct the underlying defect in CF transmembrane 
conductance regulator (CFTR) proteins have been 
shown to be effective in pwCF who have specific gene 
mutations.15 While most trials have measured respiratory 
outcomes, it is possible that these novel treatments may 
also correct some of the underlying mechanisms of GI 
problems. CFTR modulator treatment has been shown to 
be associated with weight gain16 while small uncontrolled 
studies have shown that CFTR modulators have an effect 
on small intestinal pH,17 as well as microbiota and intes-
tinal inflammation.18 Further, well- designed studies of the 
effects of CFTR modulators on GI symptoms are needed.
Limitations
Our study provides a snapshot of how patients in a small 
sample of the CF population experience GI symptoms 
and how they perceive the effectiveness of treatments 
for these symptoms. While this gives some insight into 
what professional and lay priorities might be in terms of 
future research, it may not be representative of the whole 
CF population. The UK CF Registry annual data report 
for 2018 shows that 13.2% of all registered patients have 
CFRLD compared with 20% of the participants in our 
study reporting CFRLD. Similarly there is a lower prev-
alence of DIOS in the registered population compared 
with our study population (5.2% vs 39%, respectively).2 
Furthermore, we were unable to undertake a subanal-
ysis by genotype or to look at the effects of common CF 
interventions, such as antibiotics, on symptom type and 
frequency as this was beyond the scope of our survey. 
Survey respondents are likely to be pwCF whose GI symp-
toms are particularly problematic. We asked a broad 
question: ‘Are symptoms relieved by any medication?’. 
Our data do not allow the response of specific symptoms 
to specific drugs to be analysed. Many of the medications 
prescribed for GI symptoms do not have immediate 
effects which will impact on patient reporting of the 
perceived effectiveness of each treatment.
Although the lay and professional surveys were designed 
to be very similar in terms of the questions asked, they 
could not be identical and so our results are very useful 
for giving a general picture and suggesting possible simi-
larities and differences. While we have compared the 
symptom frequency reported by patients to what profes-
sionals hear in consultations, we acknowledge that the 
two groups may not have a common language to describe 
symptoms.
Our work has shown that GI symptoms are often intru-
sive and debilitating in the daily lives of pwCF and for 
those affected can cause considerable discomfort and 
inconvenience. Many respondents talked about the 
embarrassment of dealing with GI symptoms and our 
survey has allowed pwCF to describe these anonymously, 
where they may find discussing it with their CF team 
difficult. This, along with differences in describing and 
reporting symptoms may explain some of the mismatch 
between HCP and lay responses. Our study has also high-
lighted the importance of less measurable outcomes such 
as bloating, stomach cramps and embarrassment. Future 
research around screening and reporting of GI symptoms 
in regular CF clinics would be beneficial both in terms 
of defining symptoms and identifying other conditions 
such as GI cancers.19 As treatment for CF is improving 
and people are living longer, there is the increased risk 
of developing age- related conditions which need to be 
distinguished from CF- related symptoms.
CONCLUSIONS
This study highlights some of the effects of GI symptoms 
on the lives of pwCF and identifies an area for improved 
communication with their CF team. The most common 
symptoms affecting quality of life in our study were 
bloating and stomach cramps. There is an unmet need for 
well- designed clinical studies to provide a better evidence 
base of management of GI symptoms and complications 
such as DIOS.
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